Tirzepatide restricts obesity-related tumor growth by reversing metabolic dysregulation and rescuing CD8+ T cell function
Glenny, E. M.; Coleman, M. F.; Clutton, G. T.; Riesenberg, B. P.; Ho, A. N.; McFarlane, T. L.; Kiesel, V. A.; Kucinskas, A. L.; Bailey, E. G.; Sanchez, K. E.; Zeng, J.; Wang, Y.; Malian, H. M.; Gates, C. E.; Chen, F.; Xu, R.; Holt, C. A.; Paules, E. M.; Giles, E. D.; Thaxton, J. E.; Pollak, M.; Hursting, S. D.
Show abstract
Obesity, an established risk and progression factor for at least 13 cancer types, is highly prevalent globally, and effective strategies to mitigate the burden of obesity-related cancer are urgently needed. We investigated whether tirzepatide, a widely used incretin-mimetic drug that induces substantial weight loss, offers anticancer benefits. Across 3 tumor models, we demonstrate that chronic tirzepatide treatment reverses diet-induced increases in body weight and fat mass, systemic metabolic perturbations, and tumor growth. We also showed that the anticancer activity of tirzepatide does not involve direct effects on the neoplastic cells used, which lack incretin receptor expression. The anticancer actions of tirzepatide require the reversal of both the metabolic dysregulation and hyporesponsiveness of CD8+ tumor infiltrating lymphocytes evident in obesity. Our findings establish tirzepatide as a promising compound for intercepting obesity-related cancers.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- C/EBPB-dependent Adaptation to Palmitic Acid Promotes Stemness in Hormone Receptor Negative Breast Cancer 96%
- Loss of Bone Morphogenetic Protein-binding Endothelial Regulator Causes Insulin Resistance 95%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 95%
Similar papers in this journal
Similar papers in this journal
- Lack of consistent effect of dietary fiber on immune checkpoint blockade efficacy across diverse murine tumor models 95%
- Parallel signaling through IRE1α and PERK regulates pancreatic neuroendocrine tumor growth and survival 94%
- A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma 94%
Similar papers in this journal
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 94%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 93%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.